Identification of cuproptosis-related biomarkers in dilated cardiomyopathy and potential therapeutic prediction of herbal medicines.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: LASSO, random forest and SVM-RFE selection converged on FDX1 and SLC31A1 as DCM signature genes; XGBoost assessment gave AUC/PR 0.924/0.919 in GSE141910 and 0.846/0.768 in GSE57338, with expression/ROC checks in external GSE19303 and GSE21610. The result is computational biomarker evidence, not proof of causality or herbal treatment efficacy.
Technology: LASSO, random forest and SVM-RFE selection converged on FDX1 and SLC31A1 as DCM signature genes.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- LASSO, random forest and SVM-RFE selection converged on FDX1 and SLC31A1 as DCM signature genes.
- Limitation / still unknown
- LASSO, random forest and SVM-RFE selection converged on FDX1 and SLC31A1 as DCM signature genes; XGBoost assessment gave AUC/PR 0.924/0.919 in GSE141910 and 0.846/0.768 in GSE57338, with expression/ROC checks in external GSE19303 and GSE21610. The result is computational biomarker evidence, not proof of causality or herbal treatment efficacy.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1154920/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.